Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Fibroblast Growth Factor 2.
Thèses sur le sujet « Fibroblast Growth Factor 2 »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les 50 meilleures thèses pour votre recherche sur le sujet « Fibroblast Growth Factor 2 ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Parcourez les thèses sur diverses disciplines et organisez correctement votre bibliographie.
1
Prabhudesai, Shirish G. « Fibroblast growth factor-2, chemoresistance and colorectal cancer ». Thesis, Imperial College London, 2012. http://hdl.handle.net/10044/1/10163.
Texte intégralRésumé :
Introduction: The role of fibroblast growth factor-2 (FGF-2) on colorectal cancer (CRC) cells exposed to chemotherapy has not been studied extensively. This thesis investigated whether FGF-2 mediates chemoresistance in primary (SW480) and metastatic (SW620) colon adenocarcinoma cell lines. Methods: Proliferation assays were used to assess the response of SW480 and SW620 colon cancer cell lines to varying concentrations of FGF-2 and to optimise the dose of 5- FU at which 50% cell death was observed. Cell survival assays were performed following 96 hours exposure to 5-FU ± FGF-2. Levels of chemotherapy induced apoptosis were determined using Caspase-3/7 assay. Expression of anti-apoptotic proteins (Bcl-2 and Bcl-XL) and FGFRs at both protein and gene level were determined to see if these contributed to the difference in chemoprotection observed. Results: At 0.25 ng/ml, FGF-2 did not affect proliferation in either cell lines. 25μM of 5-FU resulted in 50% kill in both cell lines. Significant cell survival was observed when FGF-2 (0.25 ng/ml) pre-treated SW620 cells were exposed to 5-FU (25 μM) compared to cells exposed to 5-FU alone (81% vs 60%, p=0.015). This chemoresistance was associated with attenuation of cellular apoptosis (p=0.04) with no significant change in expression of Bcl-2 and Bcl-XL at gene or protein level. This survival advantage was not seen in SW480 cells (59% vs 55%, p=0.35). There were no observed differences in the expression of FGFR1-4 in either cell lines. Conclusion: FGF-2 offers chemoresistance to SW620 and not to SW480 cells exposed to 5-FU. Both cell lines expressed fgf2 and fgfr1-4 genes, suggesting that fgfr expression does not account for the difference in chemoresistance. FGF-2 offered protection by causing significant reduction in chemotherapy induced apoptosis in SW620 colon cancer cell line; however this was not due to increased expression of anti-apoptotic proteins. The molecular mechanisms for this selective chemoprotection need to be investigated further.
2
Hedlund, Eva-Maria. « Molecular mechanisms of angiogenic synergism between Fibroblast Growth Factor-2 and Platelet Derived Growth Factor-BB ». Thesis, Södertörn University College, School of Life Sciences, 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:sh:diva-932.
Texte intégral
3
Shi-Lu, Chia. « The role of fibroblast growth factor-2 in articular cartilage degradation ». Thesis, Imperial College London, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.501425.
Texte intégralRésumé :
Osteoarthritis (OA) is the most common form of joint disease and a leading cause of physical disability woridwide. Cartilage degradation in OA is due to an imbalance between synthesis and degradation of the extracellular matrix. Recent work from our laboratory has shown that the heparin-binding growth factor fibroblast growth factor2 (FGF-2) mediates key responses in cartilage following mechanical trauma and loading. It has also been shown that FGF-2 is localised within the pericellular matrix, attached to the heparan sulphate proteoglycan perlecan. The spatial modulator of chondrocyte function. The primary aim of this research was to define the role of FGF-2 in cartilage degradation in vivo. Mice with deletion of Fgf2, whilst morphologically indistinguishable from wild-type animals, exhibited accelerated spontaneous and surgically-induced OA. Surgically-induced OA in Fgf2 mice was suppressed to wild type levels by subcutaneous administration of recombinant FGF-2. Increased disease in Fgf2 mice was associated with increased expression of ADAMTS-5, the key murine aggrecanase, but not other matrix metalloproteinases. Explants from Fgf2 mice showed increased aggrecanolysis and ADAMTS-5 (a disintegrin and metalloproteinase with thrombospondin motif, type 5; aggrecanase-2) gene expression following interleukin-1 (IL-1) stimulation, and exogenous FGF-2 suppressed IL-1 induced aggrecanolysis in wild-type explants. These data identify FGF-2 as a novel endogenous chondroprotective agent, and as an inhibitor of aggrecan breakdown acting through suppression of ADAMTS-5.
4
Vailes, McCauley T. « Post-Transfer Outcomes in Cultured Bovine Embryos Supplemented with Epidermal Growth Factor, Fibroblast Growth Factor 2, and Insulin-Like Growth Factor 1 ». Thesis, Virginia Tech, 2017. http://hdl.handle.net/10919/86273.
Texte intégralRésumé :
The high incidence of pregnancy loss is a major issue facing the cattle industry. Use of in vitro fertilized (IVF) bovine embryos has become increasingly popular to help alleviate several of these reproductive issues and provide a means to enhance genetic gain for production traits. An uterine paracrine factor cocktail containing epidermal growth factor (EGF), fibroblast growth factor 2 (FGF2), and insulin-like growth factor 1 (IGF1) (collectively termed EFI) was recently identified as a means for improving in vitro derived bovine embryo development and trophectoderm cell numbers. The objectives of this work were to determine if EFI treatment during in vitro bovine embryo culture improves transferable embryo quality and post-transfer placental and fetal development. For each replicate (3 total), slaughterhouse-derived bovine oocytes were matured and fertilized in vitro. At day 4 post-fertilization, ≥8 cell embryos were harvested, pooled, and exposed to either the EFI treatment (10ng/ml EGF, 10ng/ml FGF2, 50ng/ml IGF1) or carrier only (1% Bovine Serum Albumin). At day 7, individual embryos were transferred to estrous synchronized beef cattle. Artificial insemination (AI) was completed on a subset of cows. The EFI treatment increased (P<0.05) the percentage of transferable embryos. Pregnancy rate at day 28 post-estrus was similar among treatments. Circulating concentrations of pregnancy-associated glycoproteins (PAGs) were determined from plasma harvested at day 28, 42 and 56. Transrectal ultrasonography was used to measure fetal crown-rump length (CRL) at day 42 and 56 and to determine fetal sex at day 60. There were no main effect differences observed across days for PAG concentration. Fetus sex by ET/AI group interactions were absent at day 28 but existed at days 42 and 56 (P<0.05). At both days, this interaction reflected fetus sex-dependent changes within the ET control group, where PAG concentrations were greater (P<0.05) in male fetuses than female fetuses. No CRL differences or interactions existed among fetal sex and pregnancy group. In summary, addition of the EFI cocktail during bovine embryo culture improved the quality of transferable embryos, but did not affect placental function or embryonic/fetal development. Increasing the numbers of transferable embryos is of value given the cost of in vitro embryo production, but no apparent increases in embryo or placental competency were detected. The EFI treatment increased (P<0.05) the percentage of transferable embryos.Master of Science
5
Dinsdale, Jennifer Anne. « In vivo effects of fibroblast growth factor - 2 on oligodendrocytes and myelin ». Thesis, King's College London (University of London), 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.407573.
Texte intégral
6
Hannocks, Melanie-Jane. « The effects of fibroblast growth factor-2 om human bone marrow cells ». Doctoral thesis, University of Cape Town, 2003. http://hdl.handle.net/11427/2836.
Texte intégral
7
Boulle, Nathalie. « Analyse du système des insulin-like growth factors (IGF) et du fibroblast growth factor-2 (FGF-2) dans la tumorigenèse corticosurrenalienne ». Paris 11, 2000. http://www.theses.fr/2000PA11T006.
Texte intégralRésumé :
Dans les tumeurs corticosurrénaliennes, des anomalies de la région 11p15 et une surexpression du gène d'IGF-11 sont contemporaines de l'acquisition du phénotype malin. Nous montrons que la surexpression du gène IGF-11 dans les tumeurs corticosurrénaliennes malignes s'accompagne d'une traduction efficace de la protéine, majoritairement sous forme de précurseurs d'IGF-11. Ces mêmes tumeurs surexpriment de manière spécifique IGFBP-2, protéine de liaison des IGF fréquemment associée à la prolifération tumorale. La caractérisation de la lignée H295R, dérivée d'un carcinome surrénalien, montre que celle-ci surexprime IGF-11 et IGFBP-2 et constitue un bon modèle in vitro d'ét•ude de la tumorigénèse corticosurrénalienne. Cette lignée a permis de démontrer qu'IGF-11 était impliqué dans la prolifération des cellules tumorales corticosurrénaliennes via le récepteur de type 1 des IGF. L'intérêt de I'IGFBP-2 plasmatique en tant que marqueur circulant des tumeurs corticosurrénaliennes malignes a été évalué. Nous montrons que les taux d'IGFBP-2 plasmatique s'élèvent spécifiquement chez les patients porteurs de tumeurs malignes mais que cette élévation survient à lin stade avancé de la maladie (stade métastatique), indiquant la faible sensibilité d'IGFBP-2 et son intérêt limité comme marqueur des carcinomes surrénaliens. Les effets de FGF-2 sur les cellules tumorales corticosurrénaliennes ont également été étudiés. Nos résultats montrent que FGF-2 a un effet prolifératif sur les cellules H295R mais que paradoxalement, il inhibe l'expression du système des IGF par ces cellules. L'inhibition d'IGFBP-2 se fait au niveau transcriptionnel, alors que celle d'IGF-11 est post-transcriptionnelle, par inhibition de la maturation des précurseurs d'IGF-11. Ainsi, si IGF-11 a un rôle indiscutable au stade tardif de la tumorigénèse corticosurrénalienne, différents facteurs sont susceptibles de moduler son expression (FGF-2) ou son activité (IGFBP-2) au sein du tissu tumoralLn adrenocortical tumors, malignant phenotype is associated with abnormalities at the 11p15 locus and overexpression of the IGF-11 gene. Here, we show that IGF-11 mRNA is efficiently translated and that malignant adrenocortical tumors contain large amounts of IGF-11 protein, mainly in its prohormone form. The same tumors exhibit a high content in IGFBP-2 protein, an IGFBP being frequently expressed in tumor cells. The H295R cell line, which is derived from a human adrenal carcinoma, express high levels of both IGF-11 and IGFBP-2 and represents a suitable in vitro model to study adrenocortical tumorigenesis. Using this cell line, we could demonstrate that IGF-11 is involved in the proliferation of adrenocortical tumor cells, after binding to the type 1 IGF receptor. The interest of plasma IGFBP-2 as a marker for adrenocortical carcinoma was evaluated. Our results show that high levels of IGFBP-2 are specifically detected in the plasma of patients with malignant adrenocortical tumors. However, the increase in IGFBP-2 levels occur at a late stage of tumor progression (metastatic stage). This indicates a poor sensitivity for plasma IGFBP-2, which may limit its interest as a tumor marker. We also studied the effects of FGF-2 on adrenocortical tumor cells. Our results indicate that FGF-2 is mitogenic for H295R cells, although it inhibits the expression of both IGF-11 and IGFBP-2 by these cells. The inhibition of IGFBP-2 expression occur at the transcriptional levels. Ln contrast, FGF-2 inhibits the secretion and the last steps of maturation of the IGF-11 precursor. Altogether, these results suggest that in malignant adrenocortical tumors, various factors may modulate the expression (FGF-2) or the effects (IGFBP-2) of IGF-11 on adrenocortical tumor cells
8
Maucher, Tobias [Verfasser]. « Regulation des glialen Glutamattransports durch den Wachstumsfaktor ''Fibroblast growth factor 2'' (FGF-2) / Tobias Maucher ». Ulm : Universität Ulm. Medizinische Fakultät, 2004. http://d-nb.info/1015438520/34.
Texte intégral
9
SAKANAKA, MASAHIRO, SHIGERU KOBAYASHI, MINORU UEDA, TOSHIO SHIGETOMI, KENICHI KOSAKI, HIDEAKI KAGAMI et YOSHIYUKI HIRAMATSU. « THE LOCALIZATION OF BASIC FIBROBLAST GROWTH FACTOR (FGF-2) IN RAT SUBMANDIBULAR GLANDS ». Nagoya University School of Medicine, 1994. http://hdl.handle.net/2237/16076.
Texte intégral
10
Wagner, Andreas. « Identifizierung von Genen, die durch fibroblast growth factor receptor 2 (FGFR2) reguliert werden ». [S.l.] : [s.n.], 2001. http://deposit.ddb.de/cgi-bin/dokserv?idn=961705361.
Texte intégral
11
Sullivan, Christopher James. « The role of fibroblast growth factor-2 (FGF2) in vascular remodeling and adaptation ». Diss., The University of Arizona, 2002. http://hdl.handle.net/10150/284317.
Texte intégralRésumé :
The goal of this dissertation was to test the hypothesis that fibroblast growth factor-2 (FGF2) is required during diseased-related vascular growth and remodeling in the adult organism. Given previous research, it is generally assumed that FGF2 is an important regulator of vessel growth during various pathophysiological processes (e.g. tissue ischemia, vessel injury, and flow-dependent remodeling). However, such studies only indirectly implicate FGF2 in vascular adaptation and remodeling. In contrast, experiments using mice with a targeted disruption of the Fgf2 gene have allowed direct determination of the biological roles of endogenous FGF2. Thus, experimental models of flow-dependent remodeling and ischemic revascularization were used to compare the responses of Fgf2⁻/⁻ and Fgf2⁺/⁺ mice to directly identify the function of FGF2 during vascular adaptation in the adult animal. Surprisingly, the lack of FGF2 did not appear to affect vascular growth in these models. First, using a novel model of flow-dependent remodeling, Fgf2⁻/⁻ mice had equivalent carotid artery adaptation in response to both high-flow and low-flow was as wildtype counterparts. Second, angiogenesis and arteriogenesis were not different between the ischemic limbs Fgf2⁺/⁺ and Fgf2⁻/⁻ mice, demonstrating that FGF2 is not required for vascular adaptation in response to ischemia. However, these experiments led to the observation that reactive hyperemia was impaired in ischemic limb of Fgf2⁻/⁻ mice. These results indicate that vessel responsiveness is altered in the collateral circulation of the ischemic Fgf2⁻/⁻ limb. This possible identification of FGF2 as a "functional" factor in the collateral circulation suggests a novel, non-mitogenic role for endogenous growth factors. Finally, Fgf2⁻/⁻ mice had altered gene expression in the ischemic limb as evaluated using cDNA microarrays. The significance of differential gene expression in the absence of FGF2 is unknown. It is unclear whether such changes in gene expression are related to the FGF2 hyperemia phenotype or whether they are related to an unknown phenotype present in the ischemic limb of Fgf2⁻/⁻ mice. Overall, this dissertation provides new evidence that endogenous FGF2 has important actions in the remodeling vasculature during ischemic revascularization. Specifically, endogenous FGF2 appears to modulate vascular reactivity of the collateral circulation of the hindlimb.
12
Cha, Jiyoung Der Channing J. « The role and mechanism of fibroblast growth factor receptor 2 in cellular transformation ». Chapel Hill, N.C. : University of North Carolina at Chapel Hill, 2007. http://dc.lib.unc.edu/u?/etd,1513.
Texte intégralRésumé :
Thesis (Ph. D.)--University of North Carolina at Chapel Hill, 2008.Title from electronic title page (viewed Sep. 16, 2008). "... in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pharmacology." Discipline: Pharmacology; Department/School: Medicine.
13
HOUSE, STACEY LYNN. « ROLE OF FIBROBLAST GROWTH FACTOR 2 IN CARDIAC ISCHEMIA-REPERFUSION INJURY AND HYPERTROPHY ». University of Cincinnati / OhioLINK, 2005. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1132336027.
Texte intégral
14
Magnusson, Peetra. « Fibroblast Growth Factor Receptor-1 Function in Vasculo- and Angiogenesis ». Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5824.
Texte intégral
15
Kilkenny, Dawn M. « Fibroblast growth factor (FGF) receptor-1 and FGF-2 nuclear localization in proliferating growth plate chondrocytes ». Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2000. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape2/PQDD_0021/NQ58142.pdf.
Texte intégral
16
Kirtland, David Rand. « Preparation of Heparin Surface for Quantification of Fibroblast Growth Factor-2 (FGF-2) Binding Using Surface Plasmon Resonance (SPR) ». Thesis, Virginia Tech, 2005. http://hdl.handle.net/10919/33265.
Texte intégralRésumé :
A mixed self assembling monolayer (mSAM) chip with attached heparin was developed to analyze heparin-protein interactions using a Reichert Inc, SR7000, surface plasmon resonance (SPR) instrument. The heparin was attached via streptavidin-biotin linkage where the streptavidin was covalently coupled to the mSAM and biotinylated heparin bound to it. These chips were then used to quantify the interactions of fibroblast growth factor-2 (FGF-2) with the surface bound heparin. Kinetic rate constants of association and disassociation were calculated. The association data of FGF-2 with heparin was fit to a single compartment, well-mixed model as the data did not exhibit mass transfer limitations. The results suggested that rebinding was prevalent and observed disassociation rates differed significantly in the presence of competing soluble heparin during disassociation. Our results indicate that the Reichert instrument and mSAM chips can be used to analyze heparin-protein interactions but that a careful protocol, outlined in this thesis, should be followed to obtain optimal data.Master of Science
17
Fletcher, Michael. « Network analysis of fibroblast growth factor receptor 2-regulated gene expression in breast cancer ». Thesis, University of Cambridge, 2013. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.608087.
Texte intégral
18
Liao, Siyun. « The Role of Fibroblast Growth Factor-2 Isoforms in Ischemia-reperfusion Injury and Cardioprotection ». University of Cincinnati / OhioLINK, 2008. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1203690695.
Texte intégral
19
Henry, Rebecca Ann. « The effect of AAV1/2 mediated delivery of brain-derived neurotrophic factor and fibroblast growth factor-2 on adult rodent neurogenesis ». Thesis, University of Auckland, 2007. http://hdl.handle.net/2292/1492.
Texte intégralRésumé :
Neurogenesis is the process by which functionally integrated neurons are generated from progenitor cells. In the adult mammalian brain two sites of high density cell division have been identified that contain neural progenitor cells retaining the ability to generate new neurons: the subgranular zone of the hippocampus (SGZ) and the subventricular zone (SVZ) lining the lateral ventricles in the forebrain. Several studies have suggested that SVZ neural progenitor cells in the adult brain can migrate into regions other than the olfactory bulb after either administration of growth factors, induction of neuronal cell loss or injury. Brain-derived neurotrophic factor (BDNF) and fibroblast growth factor (FGF-2) play major roles in regulating the survival and fate of progenitor cells in the adult mammalian brain. To determine the effect of BDNF or FGF-2 on neurogenesis in the injured adult brain, BDNF or FGF-2 were over-expressed in the subventricular zone (SVZ) via recombinant adeno-associated virus (AAV1/2) delivery and newly generated cells were identified using bromodeoxyuridine (BrdU; 150mg/kg intraperitoneal) labelling. Selective striatal cell loss was induced in a subgroup of rats by unilateral striatal injection of the excitotoxin quinolinic acid (QA) 21 days after AAV1/2 injection and 24 hours prior to BrdU labeling. The results of this thesis demonstrate that BDNF augments the recruitment, neuronal differentiation and survival of progenitor cells in both neurogenic and non-neurogenic regions of the unlesioned or QA lesioned brain. BDNF also appears to contribute to the persistence of newly generated neurons in the QA lesioned striatum. Our results provide the first evidence demonstrating the neurogenic effect of BDNF on compensatory striatal neurogenesis in the injured adult brain and suggest that enhanced BDNF expression may be a viable strategy for inducing or augmenting endogenous neural progenitor cell neurogenesis. Unlike the effect of BDNF, FGF-2 appears to have no effect on proliferation and/or survival of neural progenitor cells in either the normal or damaged brain. FGF-2 appears to be unable to act as a positive mediator of SVZ progenitor cell proliferation and neurogenesis in this study. However, FGF-2 may be having an inhibitory effect on progenitor cell differentiation. The negative result of the FGF-2 study may be of major significance in indicating the potential requirement of additional factors interacting with FGF-2 to influence neurogenesis. The results from the FGF-2 study contribute to the research field in highlighting the complexity of the mammalian neurogenic process. This thesis highlights the need for further investigation into multiple factor interactions, tighter regulation of the transgenic protein expression from the AAV1/2 delivery vector or alternative progenitor cell labelling paradigms. However, it does show that if neurogenesis can be induced or augmented exogenously, neural progenitor cells may provide a substrate for repair in the adult brain and dramatically change therapeutic approaches towards the treatment of neurodegenerative diseases.
20
Böhm, Friederike. « Cooperative functions of fibroblast growth factor receptors 1 and 2 in liver homeostasis and regeneration / ». [S.l.] : [s.n.], 2009. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=18385.
Texte intégral
21
Debiais, Françoise. « Effets et mecanismes d'action du fibroblast growth factor-2 sur les osteoblastes de calvaria humaine ». Paris 7, 2000. http://www.theses.fr/2000PA077058.
Texte intégralRésumé :
Plusieurs arguments laissent penser que le fgf-2 joue un role important dans le controle de la formation osseuse. Cependant, les mecanismes cellulaires et moleculaires par lesquels le fgf-2 peut moduler l'osteogenese sont peu connus. Nous avons etudie les effets de ce facteur de croissance et ses mecanismes d'action en utilisant des cellules osteoblastiques issues de la voute cranienne de nourrissons, constituant un nouveau modele osteogenique recemment developpe dans le laboratoire. Nous avons montre que ces cellules humaines de calvaria expriment les recepteurs fgfr1 et fgfr2 et sont donc des cellules cibles pour le fgf-2. Nous avons precise que le fgf-2 a un effet mitogene, module la differenciation de ces osteoblastes humains de calvaria de facon differente en fonction du stade de maturation cellulaire et peut donc augmenter l'osteogenese par les cellules differenciees. Nous avons mis en evidence pour la premiere fois que la n-cadherine est un gene cible pour le fgf-2 dans ces cellules. Le fgf-2 stimule l'expression de la n-cadherine et augmente l'agregation cellulaire ; cet effet implique les voies de signalisation pkc et src. Les resultats preliminaires de notre etude concernant l'apoptose suggerent un effet initial anti-apoptotique, qui pourrait etre suivi d'un effet pro-apoptotique. Le fgf-2 pourrait ainsi reguler l'osteogenese de la calvaria en favorisant l'adhesion des cellules osteoblastiques au stade precoce de condensation mesenchymateuse. Le fgf-2 augmente la proliferation puis la differenciation des cellules osteoblastiques de facon variable en fonction du stade de differenciation cellulaire, et enfin regule l'apoptose de ces cellules. Ces resultats contribuent a expliquer les effets anaboliques du fgf-2 retrouves
22
McKenty, Taylor R. « QUANTIFYING THE EFFECTS OF HYDROSTATIC PRESSURE ON FIBROBLAST GROWTH FACTOR-2 BINDING BY THE HUMAN ENDOTHELIUM ». UKnowledge, 2017. http://uknowledge.uky.edu/cbme_etds/47.
Texte intégralRésumé :
Fluid pressures regulate endothelial cell (EC) tubulogenic activity involving fibroblast growth factor 2 (FGF-2) and its receptor, FGF receptor 2 (FGFR2). Our lab has recently shown that sustained 20 mmHg hydrostatic pressure (HP) upregulates EC sprout formation in a FGF2-dependent fashion. This upregulation of sprout formation may be due to enhanced FGF-2 / FGFR2 interactions in the presence of 20 mmHg HP. We hypothesize that exposure of ECs to 20 mmHg sustained HP enhances FGF-2 binding kinetics. We used a custom hydrostatic pressure system, immunofluorescence, and FACS to quantify FGF-2 binding by ECs in the absence or presence of a range of HPs for 30 minutes. Relative to cells maintained under control pressure, ECs exposed to 20, but neither 5 nor 40 mmHg, displayed a significant increase in binding affinity to FGF-2. EC binding of VEGF-A, another angiogenic growth factor, was unaffected by similar pressure stimuli. Additional studies showed that pressure-selective FGF-2 binding was independent of FGFR2 surface expression. These results implicate the FGF-2 axis in the pressure-sensitive, magnitude-dependent angiogenic processes which we have previously described. The present study provides novel insight regarding the involvement of FGF-2 signaling and interstitial pressure changes in various microvascular physiological and pathobiological processes.
23
Kole, Denis. « Role of Fibroblast Growth Factor 2 in Maintenance of Multipotency in Human Dermal Fibroblasts Treated with Xenopus Laevis Egg Extract Fractions ». Digital WPI, 2014. https://digitalcommons.wpi.edu/etd-dissertations/207.
Texte intégralRésumé :
Current usage of human embryonic stem cells (hES) and induced pluripotent stem cells (iPS) in clinical therapies and personalized medicine are limited as a result of ethical, technical and medical problems that arise from isolation and generation of these cells. Isolation of hES cells faces ethical problems associated with their derivation from human pre-implantation embryos. The most controversial aspect of hES cell isolation targets the generation of autologous hES cell lines which requires the transfer of a somatic-cell nucleus from the patient to an enucleated oocyte. While already established embryonic stem cell lines from IVF embryos can be used in a similar manner, lack of genetic identity can cause therapy rejection from the host, and prevent their use in personalized medicine. Induced pluripotent stem cells on the other hand, are generated from somatic cells that have been reprogrammed in vitro to behave like stem cells. While these cells can potentially be used for personalized medicine without the risk of rejection by the host system, derivation methods prevent their therapeutic use. The most efficient method used to generate iPS cells involves usage of viral particles which can result in viral DNA being integrated in the host cell’s genome and render these cells non-compliant for clinical therapies. Other methods not involving viral particles exist as well, but the reprogramming efficiency is too low and technical problems with generating large enough numbers of cells prevent these methods from being feasible approaches for clinical therapies. Direct reprogramming of a differentiated cell into a developmentally more plastic cell would offer alternatives to applications in regenerative medicine that currently depend on either embryonic stem cells (ES), adult stem cells or iPS cells. We hypothesize that Xenopus laevis egg cytoplasmic extract contains critical factors needed for reprogramming that may allow for non-viral, chemically defined derivation of human induced pluripotent/multipotent cells which can be maintained by addition of exogenous FGF2. In this thesis we investigated a new method for generation of multipotent cells through determining the ability of select fractions of Xenopus laevis egg extract to induce multipotency in already differentiated cells. We were able to identify select fractions from the extract that in combination with exogenously added FGF2 can reprogram and maintain the reprogrammed cells in an undifferentiated state. The findings of this work also determined that Xenopus laevis egg extract mRNA is required for achieving full reprogramming. The body of work presented in this thesis showed the ability of FGF2 isoforms to bind and activate select FGF receptor tyrosine kinases, act as extracellular mitogenic factors to support growth of hES cells in an undifferentiated state as well bind to nuclear DNA and affect expression of endogenous genes. Moreover, we showed that all FGF2 isoforms can induce expression of stem cell specific proteins in human dermal fibroblasts as well as extend lifespan of human dermal fibroblasts in vitro. In this work we identified HECW1, the gene coding for E3 ubiquitin ligase NEDL1, as a novel nuclear target for all FGF2 isoforms and showed that overexpression of recombinant FGF2 isoforms in human dermal fibroblasts can down regulate expression of HECW1 gene.
24
Bossé, Ynuk. « Interactions between fibroblast growth factor 2 and distinct asthma mediators enhance bronchial smooth muscle cell proliferation ». Thèse, Université de Sherbrooke, 2006. http://savoirs.usherbrooke.ca/handle/11143/4235.
Texte intégralRésumé :
Increased bulk of smooth muscle mass around the airways is a typical feature of asthma. Several mediators act in concert or antagonistically to regulate airway smooth muscle (ASM) cell proliferation. This thesis focuses on fibroblast growth factor (FGF)2 and transforming growth factor (TGF)[béta]1 which are known to be sequentially upregulated in the lung following allergic challenge and have recently been shown to synergize together in ASM cell proliferation. Emphasis is put toward the conflicting studies documenting the mitogenic effect of TGF[béta]1 in vitro and to its seemingly potent effect in vivo. Thereafter, different asthma mediators, such as IL-4 and IL-13, are introduced and how their mitogenic potential toward ASM cells could be altered by FGF2 is presented. Finally, how the controversial issue between in vitro and in vivo data regarding the mitogenic effect of leukotrienes could be reconciliated and how it could be related to FGF2 and TGF[béta]1 proliferative synergism is discussed.
25
Sheikh, Farah. « Regulation of the fibroblast growth factor-2 axis in cardiac cells, effects on cardioprotection and cardiac muscle cell growth ». Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2001. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp05/NQ62665.pdf.
Texte intégral
26
Ehrenfels, Yvonne. « Mutationen in den "fibroblast growth factor" (FGF)-Rezeptorgenen FGFR 1, 2 und 3 bei primären Craniosynostosen ». [S.l.] : [s.n.], 2000. http://deposit.ddb.de/cgi-bin/dokserv?idn=960357629.
Texte intégral
27
Bossé, Ynuk. « Interactions between fibroblast growth factor 2 and distinct asthma mediators enhance bronchial smooth muscle cell proliferation ». [S.l. : s.n.], 2006.
Trouver le texte intégral
28
Santiago, Jon-Jon. « Studies on high molecular weight fibroblast growth factor-2 isoforms produced by rat and human cardiac myofibroblasts ». Oxford Journals, 2011. http://hdl.handle.net/1993/23867.
Texte intégralRésumé :
Fibroblast growth factor-2 (FGF-2) is expressed as high molecular weight (> 20 kDa, Hi-FGF-2), or low molecular weight, (18 kDa, Lo-FGF-2) isoforms with distinct functions in the heart and other tissues. Studies to-date have focused on Lo-FGF-2, while the biology of Hi-FGF-2 is less well understood. This work investigated potential autocrine and paracrine effects of rat and human Hi-FGF-2 on cardiac myocytes and non-myocytes (myofibroblasts).
Using rat ventricular myofibroblast cultures stimulated with angiotensin II (Ang II), in the absence or presence of YVAD, a peptide inhibitor of caspase-1, it was shown that caspase-1 activity was required for the Ang II-stimulated Hi-FGF-2 secretion. Secreted rat Hi-FGF-2 was shown to be biologically active and capable of stimulating neonatal as well as adult cardiomyocyte hypertrophy in vitro. The effect of extracellular-acting Hi- versus Lo-FGF-2 on the secretome profile of rat cardiac myofibroblasts was compared. Conditioned media collected after stimulation with rat Hi- or Lo-FGF-2 were analyzed by mass spectroscopy (LC-MS/MS). Secretome profiles suggested that Hi-FGF-2 was more potent than Lo-FGF-2 in upregulating several matricellular and fibrosis-associated proteins, most prominently periostin, follistatin-like protein 1, plasminogen activator inhibitor-1, and tenascin.
Human heart (atrial) tissue, pericardial fluid, and human heart-derived myofibroblasts were shown to accumulate predominantly Hi-FGF-2. Ang II up-regulated Hi-FGF-2 in human cells, via activation of: type 1 or type 2 Ang II receptors (AT-1R, AT-2R); the ERK pathway; and matrix metalloprotease-2. Neutralizing antibodies specific for Hi-FGF-2 (neu-AbHi-FGF-2) reduced expression of proteins associated with fibroblast-to-myofibroblast conversion and fibrosis. Blocking the autocrine action of Hi-FGF-2 on human cells with neu-AbHi-FGF-2 resulted in down-regulation of periostin, as well as α-smooth muscle actin, pro-collagen, embryonic smooth muscle myosin, and extra domain A fibronectin, consistent with a reversal from activated myofibroblast to fibroblast phenotype. Stimulation of human myofibroblasts with human Hi-FGF-2 was significantly more potent than Lo-FGF-2 in upregulating pro-interleukin-1β and plasminogen activator inhibitor-1, considered to be pro-inflammatory proteins.
It is concluded that exported, extracellular-acting Hi-FGF-2 has pro-fibrotic, pro-inflammatory, and pro-hypertrophic properties, contributes to the ‘activated fibroblast’ phenotype, and represents a therapeutic target for prevention of maladaptive cardiac remodeling in humans.
29
Olson, Nels Eric. « FGF2 is weakly mitogenic for intimal smooth muscle cells : role of FGF receptor expression, cytoplasmic signaling and cell cycle regulation / ». Thesis, Connect to this title online ; UW restricted, 2000. http://hdl.handle.net/1773/6335.
Texte intégral
30
Padua, Raymond Ronald. « The cardioprotective effects of fibroblast growth factor-2 against ischemia-reperfusion injury in the isolated rat heart ». Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk2/ftp03/NQ32013.pdf.
Texte intégral
31
Wang, David I. Kuo. « The effects of fibroblast growth factor 2 on the early stages on in vitro endothelial wound repair ». Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape11/PQDD_0013/MQ40777.pdf.
Texte intégral
32
Perlyn, Chad. « Signalling paradigms of fibroblast growth factor receptor type 2 : studies from a Crouzon-Pfeiffer syndrome mouse model ». Thesis, University of Oxford, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.433337.
Texte intégral
33
Zacherl, Sonja [Verfasser], et Walter [Akademischer Betreuer] Nickel. « A Role for ATP1A1 in Unconventional Secretion of Fibroblast Growth Factor 2 / Sonja Zacherl ; Betreuer : Walter Nickel ». Heidelberg : Universitätsbibliothek Heidelberg, 2014. http://d-nb.info/1177888823/34.
Texte intégral
34
Morss, Alisa Sharon. « Endothelial cells and basement membrane : a co-regulatory unit for fibroblast growth factor-2 in hyperglycemic stress ». Thesis, Massachusetts Institute of Technology, 2006. http://hdl.handle.net/1721.1/36167.
Texte intégralRésumé :
Thesis (Ph. D.)--Harvard-MIT Division of Health Sciences and Technology, 2006.Includes bibliographical references.
Endothelial cells and basement membrane interact as a biochemical and mechanical co-regulatory unit. The wide spectrum of manifestations of diabetic vascular disease could be related to altered kinetics of vasoactive compounds within this regulatory unit. We hypothesized that hyperglycemic stress mediates storage, release, and function of fibroblast growth factor-2 (FGF-2) through changes in interaction between endothelial cells and basement membrane. We discovered that basement membrane associated FGF-2 increased linearly with culture glucose concentration. Using novel assays, we demonstrated that FGF-2 binding kinetics were surprisingly unchanged over a range of basement membrane culture glucose. Instead, the combination of increased endothelial cell apoptosis-associated FGF-2 release and enhanced endothelial cell permeability allowed more FGF-2 to bind into the basement membrane. Such high levels of basement membrane FGF-2 abrogated the effects of hyperglycemia on proliferation but not apoptosis. An FGF-2 stimulus returned endothelial cell proliferation close to euglycemic levels, but increased apoptosis was still evident as FGF-2 signaling down an intracellular survival pathway was inhibited by glucose.
(cont.) These same findings were confirmed in vivo where FGF-2 levels were elevated in the aortic subendothelial space of diabetic animals. This thesis suggests a new paradigm for active cellular control of basement membrane and indicates the complexities of growth factor signaling in endothelial cells. Characterization of the interaction between endothelial cells and basement membrane in health and disease may advance our understanding of diabetic vascular disease and lead to development of novel biomimetic materials for therapeutic intervention.
by Alisa Sharon Morss.
Ph.D.
35
Harfouche, L'Emira Ghida. « Fibroblast growth factor 2 and DNA repair involvement in the keratinocyte stem cells response to ionizing radiation ». Paris 11, 2010. http://www.theses.fr/2010PA11T002.
Texte intégral
36
Burger, Patricia E. « The effects of fibroblast growth factor-2 (FGF-2) on haematopoietic cells and the identification of those cells expressing FGF receptors ». Doctoral thesis, University of Cape Town, 2002. http://hdl.handle.net/11427/3110.
Texte intégral
37
Brooks, Nicole E. « Fibroblast Growth Factor 21 Expression in Mice with Altered Growth Hormone Action : Links to Obesity, Type 2 Diabetes Mellitus, and Increased Longevity ». Ohio University Honors Tutorial College / OhioLINK, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=ouhonors1461161246.
Texte intégral
38
Desgranges, Pascal. « Effets du fibroblast growth factor 2, de l'héparine et des molécules "heparan-like" sur l'endothélialisation de prothèses vasculaires ». Paris 12, 1995. http://www.theses.fr/1995PA120017.
Texte intégralRésumé :
L'endothélialisation des surfaces internes des prothèses de petit calibre pourrait améliorer leur taux de perméabilité. Trois solutions sont envisageables : 1) l'ensemencement de cellules endothéliales (CE), 2) la migration transanastomotique ou 3) la migration transprothétique des CE. Dans ce travail, nous avons montré qu'in vitro, l'association de fibroblast growth factor 2 (FGF2), d'héparine ou de molécules heparan-like appelés carboxyméthyl benzylamide sulfonate dextrane (CMDBS) imprégnée sur une prothèse de polyéthylène téréphtalate (PET) favorisait la prolifération et la migration des CE. La migration transprothétique est augmentée quand les CE sont cultivées en présence de l'association FGF2 et CMDBS. L'adjonction de FGF2, d'héparine et de CMDBS dans l'environnement prothétique pourrait favoriser in vivo l'endothélialisation de prothèses vasculaires selon les trois mécanismes : l'ensemencement, la migration transanastomotique et la migration transprothétique.
39
Kinkl, Norbert. « Mechanisms of action of fibroblast growth factor 2 (FGF2) in rat retinal cells : photoreceptor survival and intracellular signaling ». Université Louis Pasteur (Strasbourg) (1971-2008), 2001. http://www.theses.fr/2001STR13166.
Texte intégralRésumé :
La dégénérescence des photorécepteurs est à l'origine de nombreuses pathologies rétiniennes aboutissant à une malvoyance voire à la cécité. Les facteurs neurotrophiques représentent une approche thérapeutique potentielle. Au cours de cette thèse nous nous sommes intéressés aux mécanismes d'actions in vitro d'un facteur neurotrophique exprimé dans la rétine, le FGF2. Afin d'étudier les effets directs du FGF2 sur la survie des photorécepteurs, nous avons mis au point un nouveau modèle de culture pure en photorécepteurs à partir de rétine jeune de rat. La pureté en photorécepteurs des cultures est > 99,5%, les cellules gliales de Müller (CGM) représentant < 0,5% de la population cellulaire. Grâce à ce modèle, nous avons montré que le FGF2 stimule la survie des photorécepteurs in vitro et qu'un autre facteur neurotrophique, l'EGF, accélère leur dégénérescence, en activant leurs récepteurs respectifs à activité tyrosine kinase. Les FGFR1-4 ainsi que différentes protéines impliquées dans la transduction du signal du FGF2 (ERK1/2, MEK1, MEK2, PLCg1, SHPTP-2, SOS1, SOS2, Grb2, Shc, Akt), sont exprimés de façon ubiquitaire, mais possèdent des niveau d'expression distinct, selon les différentes populations de cellules rétiniennes (photorécepteurs, rétine interne et CGM) in vivo et in vitro. Néanmoins, le FGF2 y induit des cascades de signalisation distinctes. Ceci indique l'existence de différentes voies de transduction du signal au FGF2 dans la rétine aboutissant toutes à l'activation de ERK1/2. L'inhibition pharmacologique de MEK bloque l'activation de ERK1/2 dans les photorécepteurs et inhibe leur survie induit par le FGF2, alors qu'au niveau des cellules de la rétine interne et des CGM, le FGF2 stimule également des voies d'activation de ERK1/2 indépendantes de MEK. L'ensemble de ces résultats apporte des données originales concernant les effets du FGF2 sur la survie des photorécepteurs ainsi que sur sa signalisation dans la rétine de rat in vitro, et pourrait contribuer à une application potentielle du FGF2 dans une approche clinique.
40
Elahouel, Rania. « Le Fibroblast Growth Factor 2 ( FGF-2 ) et la neuropiline-1 (NRP-1) : nouveaux partenaires moléculaires de Heparin Affin Regulatory Peptide ( HARP) ». Thesis, Paris Est, 2012. http://www.theses.fr/2012PEST0066.
Texte intégralRésumé :
HARP (Heparin Affin regulatory peptide) est un facteur de croissance qui constitue avec la midkine une sous-famille des Heparin Binding Growth Factors (HBGFs). HARP est impliqué dans de nombreux processus physiologiques comme la neurogenèse et la vasculogenèse mais aussi dans des processus physiopathologiques comme l’angiogenèse et la progression tumorale. HARP interagit avec différents récepteurs (N-syndécan, RPTPβ/ζ, et ALK). Plus récemment, il a été montré au laboratoire que la nucléoline, protéine navette entre le noyau, le cytoplasme, et la surface cellulaire est un nouveau récepteur à HARP. Malgré les avancées dans ce domaine, l’interaction de HARP avec ses récepteurs n’est pas totalement élucidée. L'objectif de ce projet de thèse était la recherche de nouveaux partenaires moléculaires qui interagissent avec HARP, de comprendre le mécanisme de leurs interaction et d’analyser les effets biologiques. A ce titre, j’ai participé à l’étude de l’interaction de HARP avec le facteur de croissance des fibroblastes, le FGF-2. Ce facteur liant l’héparine est également mitogène et angiogène. En utilisant des techniques de biocapteurs optiques et d’interaction protéine-protéine, nous avons montré une interaction directe entre HARP et le FGF-2 et qui implique les domaines C-TSR-I et C-terminale de HARP. De plus, cette interaction inhibe la migration et la prolifération des cellules endothéliales, induites par le FGF-2 ou par HARP seuls. En parallèle, j’ai mis en évidence l’interaction entre HARP et la NRP-1. NRP-1 est une protéine transmembranaire, ayant comme ligands principaux, les sémaphorines de classe 3 (SEMA 3A), le facteur de croissance endothélial vasculaire (VEGF) et le FGF-2. En plus de son rôle crucial dans le développement des systèmes nerveux et cardiovasculaires, la NRP-1 est impliquée dans les processus physiopathologiques tels que l’angiogenèse et l’invasion tumorale. Ainsi, la NRP-1 présente un profil biologique similaire à HARP. En utilisant des tests d’ELISA, d’immunoprécipitation et de « pull-down », nous avons montré que HARP interagit avec la NRP-1. Cette interaction semble être directe et s’effectue via les domaines de liaison à l’héparine TSR-I. HARP induit l’internalisation de la NRP-1 au bout de 15 minutes et son recyclage partiel à la surface cellulaire au bout d’une heure. L’internalisation de la NRP-1 s’accompagne par la phosphorylation des voies MAPK (ERK1/2), Akt et FAK. L’interaction HARP/NRP-1 est cruciale pour la migration des cellules endothéliales et l’invasion des cellules tumorales. En conclusion, ces résultats apportent de nouvelles avancées concernant les partenaires moléculaires de HARP en particulier et montrent également la complexité des interactions des facteurs de croissance entre eux et avec leurs récepteurs. Plus généralement, cette étude permet d'envisager des stratégies thérapeutiques ciblant l’interaction de la NRP-1 avec HARP et aussi les autres facteurs de croissanceHARP (Heparin Affin regulatory peptide) is a growth factor that constitutes with midkine a subfamily of Heparin Binding Growth Factors (HBGFs). HARP is involved in many physiological processes such as neurogenesis and vasculogenesis but also in pathophysiological processes such as angiogenesis and tumor progression. HARP interacts with different receptors (N-syndecan, RPTPβ / ζ and ALK). More recently, it has been shown in the laboratory that nucleolin, a protein shuttle between the nucleus, cytoplasm, and cell surface, is a new HARP receptor. Despite the advances in this field, the interaction of HARP with its receptors is not fully understood. The aim of this thesis was the search for new molecular partners that interact with HARP, to understand the mechanism of their interaction and analyze the biological effects. My work was firstly to participate to the study of the interaction of HARP with the fibroblast growth factor-2, FGF-2. This factor is also an heparin-binding factor, with mitogenic and angiogenic activities. Using techniques of optical biosensors and protein-protein interaction, we have shown a direct interaction between HARP and FGF-2 that involves C-TSR-I and C-terminus domains of HARP. In addition, HARP inhibits the migration and proliferation of endothelial cells induced by FGF-2. In parallel, I highlighted the interaction between HARP and NRP-1. NRP-1 is a transmembrane protein having as main ligands, semaphorins class 3 (SEMA 3A), the vascular endothelial growth factor (VEGF) and FGF-2. In addition to its crucial role in the development of the nervous and cardiovascular systems, the NRP-1 is involved in physiopathological processes such as angiogenesis and tumor invasion. Thus, NRP-1 has a biological profile similar to HARP. Using ELISA, immunoprecipitation and "pull-down" tests, we have shown that HARP interacts with NRP-1. This interaction appears to be direct and occurs via heparin binding domains of HARP: TSR-I. HARP induces internalization of NRP-1 after 15 minutes and partial recycling to the cell surface after one hour. The internalization of the NRP-1 is accompanied by the phosphorylation of MAPK pathways (ERK1 / 2), Akt and FAK. HARP/NRP-1 interaction is crucial for endothelial cell migration and invasion of tumor cells. In conclusion, these results provide new advances on molecular partners of HARP in particular and also show the complexity of the interactions between these growth factors and their receptors. More generally, this study allows considering therapeutic strategies targeting the interaction of NRP-1 with HARP as well as other growth factors
41
Robbez-Masson, Luisa. « Investigating the functional significance of an FGFR2 intronic SNP in breast cancer ». Thesis, Queen Mary, University of London, 2013. http://qmro.qmul.ac.uk/xmlui/handle/123456789/8539.
Texte intégralRésumé :
Single nucleotide polymorphisms present in the second intron of the fibroblast growth factor receptor 2 (FGFR2) gene have been linked with increased risk of breast cancer in several genome wide association studies. The potential effect of those SNPs appeared to be mediated through the differential binding of cis-regulatory elements, such as transcription factors, since all the SNPs in linkage disequilibrium were located in a regulatory DNA region. Preliminary studies have shown that a Runx2 binding site is functional only in the minor, disease associated allele of rs2981578, resulting in increased expression of FGFR2 in cancers from patients homozygous for that allele. Moreover, the increased risk conferred by the minor FGFR2 allele is associated most strongly in oestrogen receptor alpha positive (ERα) breast tumours, suggesting a potential interaction between ERα and FGFR signalling. Here, we have developed a human cell line model system to study the effect of those SNPs on cell behaviour. In an ERα positive breast cancer cell line, rs2981578 was edited using Zinc Finger Nucleases. Unexpectedly, the acquisition of the single risk allele in MCF7 cells failed to affect proliferation or cell cycle progression. Binding of Runx2 to the risk allele was not observed. However FOXA1 binding, an important ERα partner, appeared decreased at the rs2981578 locus in the risk allele cells. Additionally, differences in allele specific expression (ASE) of FGFR2 were not observed in a panel of 72 ERα positive breast cancer samples. Thus, the apparent increased risk of developing ERα positive breast cancer is not caused by rs2981578 alone. Rather, the observed increased risk of developing breast cancer might be the result of a coordinated effect of multiple SNPs forming a risk haplotype in the second intron of FGFR2.
42
Adeyemo, Adeola T. « The Roles of the High and Low Molecular Weight Isoforms of Fibroblast Growth Factor 2 in Ischemia-Induced Revascularization ». University of Cincinnati / OhioLINK, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1460444581.
Texte intégral
43
Machado, Aline Zamboni. « Pesquisa de mutações nos genes FGF9 e FGFR2 em pacientes portadores de distúrbios do desenvolvimento sexual 46,XY por anormalidades no desenvolvimento gonadal ». Universidade de São Paulo, 2012. http://www.teses.usp.br/teses/disponiveis/5/5135/tde-18092012-143903/.
Texte intégralRésumé :
Introdução: Várias evidências em estudos de animais knockout sugerem a efetiva participação dos genes Fgf9-Fgfr2 no processo de determinação testicular. Animais XY knockout para os genes Fgf9 e Fgfr2 apresentam reversão sexual como consequência da alteração na cascata de eventos masculinizantes nas gônadas fetais. Até o momento, mutações inativadoras dos genes FGF9-FGFR2 não foram descritas em pacientes 46, XY portadores de disgenesia gonadal. Objetivos: Pesquisar a presença de mutações inativadoras nos genes FGF9 e FGFR2 em pacientes portadores de DDS 46,XY por anormalidades do desenvolvimento gonadal. Casuística e Métodos: Trinta e três pacientes com disgenesia gonadal 46, XY, 11 com a forma completa e 22 com a forma parcial. As regiões codificadoras dos genes FGF9 e FGFR2 de todos os pacientes foram amplificadas e sequenciadas. As investigações quanto a presença de deleções foram realizadas usando-se a técnica de MLPA (Multiplex ligation-dependent probe amplification). Resultados: Mutações ou deleções nos genes FGF9 não foram encontradas em nenhum dos pacientes estudados, apenas alguns polimorfismos previamente descritos. No gene FGFR2 não foram encontradas deleções. Uma nova variante não sinônima em heterozigose, c.1358 C>T (p.Ser453Leu), localizada no exon 10 do FGFR2 foi encontrada em duas irmãs com disgenesia gonadal parcial 46,XY. A mãe é portadora da variante alélica e o estudo de 147 indivíduos controles não identificou a presença desta variante. A análise da variante em sites de previsão, PolyPhen, SIFT e Mutation Taster indicou que a nova proteína FGFR2 é possivelmente danificada. Conclusões: Se esses resultados dos sites de previsão forem confirmados em estudos funcionais futuros a participação do gene FGFR2 na determinação gonadal masculina em humanos estará comprovadaIntroduction: Several evidence in animal studies \"knockout\" suggest the effective participation of Fgf9-Fgfr2 genes in testicular determination process. Animals XY \"knockout\" for Fgf9 and Fgfr2 genes exhibit sex reversal as a result of the change in the cascade of masculinizing events in fetal gonads. To date, So far inactivating mutations of FGF9 and FGFR2 genes have not been described in 46,XY patients with gonadal dysgenesis. Objectives: To investigate the presence of inactivating mutations in the FGF9 and FGFR2 gene in patients with 46,XY DSD by gonadal abnormalities. Casuistic and Methods: Thirty-three patients with 46,XY gonadal dysgenesis, 11 with the full form and 22 with the partial form. The coding regions of FGF9 and FGFR2 genes of all patients were amplified and sequenced. Investigations on the presence of deletions were made using the MLPA technique (\"Multiplex ligation-dependent probe amplification\"). Results: Mutations or deletions in the FGF9 gene were not found in any of the patients studied, only a few polymorphisms previously described. FGFR2 gene deletions were not found. A new non-synonymous variant in heterozygosis, c.1358 C> T (p.Ser453Leu) located in exon 10 of FGFR2 was found in two sisters with 46,XY partial gonadal dysgenesis. The mother is a carrier of the variant allele and the study of 147 control subjects did not identify the presence of this variant. The analysis of the variant on prediction sites, \"PolyPhen\", \"SIFT\" and \"Mutation Taster\" indicated that the new FGFR2 protein is possibly damaged. Conclusions: If the results of the prediction sites are confirmed by future functional studies the participation of the FGFR2 gene in human male gonadal determination will be proven
44
Kefalakes, Ekaterini Sofia [Verfasser]. « Role and putative therapeutic implications of fibroblast growth factor-2 (FGF-2)-dependent interplay of neurotrophic factors and signaling cascades in amyotrophic lateral sclerosis / Ekaterini Sofia Kefalakes ». Hannover : Stiftung Tierärztliche Hochschule Hannover, 2018. http://d-nb.info/1178008851/34.
Texte intégral
45
Ritchey, Eric R. « Regulation of Ocular Growth in Wild-Type and Retinopathy, Globe Enlarged (RGE) Chickens ». The Ohio State University, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=osu1313530021.
Texte intégral
46
Filani, Oluwadamilola. « Expression and Purification of Unlabelled and Isotopically Labelled Human Fibroblast Growth Factor-1 and its Receptor Relevance in Cancer Research ». TopSCHOLAR®, 2015. http://digitalcommons.wku.edu/theses/1549.
Texte intégralRésumé :
Studies show that fibroblast growth factors (FGFs) control variety of cellular activities such as mitosis, cell differentiation, survival and angiogenesis. The FGF family consists of 23 different heparin-binding proteins. One of the most intensively studied members is human FGF-1 (hFGF-1) because of its critical role in the formation of blood vessels and cell proliferation in some types of cancer. The biological activities of FGFs are primarily mediated via interactions with fibroblast growth factor receptors (FGFR) and are a potent target in cancer. In this study, we report an efficient affinity column purification of hFGF-1 and the D2 domain of FGFR-2 from bacterial expression followed by SDSPAGE analysis. Steady state fluorescence results showed that both proteins were in their native conformation. The 1 H-15N HSQC NMR analysis of hFGF-1 was further performed. The data confirmed the purity and well-conserved native state of the protein. The findings of this study can be used in designing hFGF-1 antagonists with competitive inhibition characteristics. These antagonists could result in possible inhibition of hFGF-1 cell proliferation and angiogenesis associated in tumorigenesis.
47
Aguiar, Rodrigo Barbosa de. « Aplicação diagnóstica e terapêutica de um novo anticorpo anti-FGF2 em processos de angiogênese em melanoma experimental ». Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/5/5155/tde-29102014-162446/.
Texte intégralRésumé :
Evidências sugerem que o fator de crescimento de fibroblasto 2 (FGF2), produzido por melanomas, possui importante papel no crescimento tumoral, angiogênese e metástase. Assim, o uso de anticorpo monoclonal (mAb) que reconhece e bloqueia a atividade de FGF2 é uma abordagem a ser considerada em oncologia. O propósito desse estudo foi avaliar a aplicação diagnóstica e terapêutica de um novo anticorpo anti-FGF2, 3F12E7 IgG1, em melanoma experimental B16-F10. Para isso, camundongos C57Bl/6 foram implantados subcutaneamente (ou intravenosamente, para ensaios de metástase) com células de melanoma murino B16-F10 (5x105 células/animal). Quando tumores alcançaram 3-4 mm de diâmetro (ou 24 h pós-inóculo de células B16-F10, no caso de ensaios de metástase), camundongos foram tratados com anti-FGF2 3F12E7 IgG. Animais controle receberam igual volume do veículo ou quantidade de anticorpo controle de isotipo. Grupos: animais tratados com (1) anti-FGF2 3F12E7 IgG1; (2) ligante de CEA IgG1 (controle de isotipo); e (3) veículo. O tratamento dos camundongos portadores de tumor com anti-FGF2 IgG resultou, comparado com os controles salina e de isotipo, em uma redução no número de focos metastáticos nos pulmões (ANOVA, p < 0,05), em ensaios de metástase experimental, bem como em uma menor taxa de crescimento de tumores subcutâneos (n=7/grupo). Esse resultado é acompanhado por uma redução na densidade vascular do tumor, conforme determinado por imunomarcação para CD34 ou CD31. A captação tumoral de anti-FGF2 3F12E7 IgG foi avaliada por métodos de medicina nuclear, usando esse anticorpo radiomarcado com tecnécio-99m. Estudos SPECT/CT in vivo e de biodistribuição ex vivo revelaram que 99mTc-anti-FGF2 3F12E7 IgG pode atingir eficientemente tumores subcutâneos e metastáticos de B16-F10. Assim, esses dados sugerem que anti-FGF2 3F12E7 IgG pode ser uma estratégia antitumoral promissora para melanoma, bem como uma potencial ferramenta de imagem a ser explorada, atuando como um possível traçador para rastrear tumores FGF2-positivos e mapear esse estímulo angiogênico no microambiente tumoral. Aprovado pelo comitê de ética (CAPPesq): número 0942/09Compelling evidence suggests that fibroblast growth factor 2 (FGF2), produced by melanomas, plays important role in tumor growth, angiogenesis and metastasis. Therefore, the use of a monoclonal antibody (mAb) that recognizes and blocks FGF2 activity is seen as an approach to be considered in oncology. The purpose of this study was to evaluate the diagnostic and therapeutic application of a new anti-FGF2 antibody, 3F12E7 IgG1, in experimental melanoma B16-F10. For this, C57Bl/6 mice were subcutaneously (or intravenously, for experimental metastasis assay) implanted with murine melanoma B16-F10 cells (5x105 cells/animal). When tumors reached 3-4 mm in diameter (or 24 h after B16-F10 cells injection, in the case of metastasis assay), mice started receiving anti-FGF2 3F12E7 IgG. Control mice received equal volume of vehicle or isotype control IgG amount. Groups: (1) anti-FGF2 3F12E7 IgG1-treated, (2) CEA-binding IgG1-treated (isotype control) and (3) vehicle-treated mice. The treatment of tumor-bearing mice with anti-FGF2 IgG, compared with saline and isotype controls, led to a reduction in the number of metastatic foci in the lungs (ANOVA test, p < 0.05), in experimental metastasis assays, as well as to a lower subcutaneous tumor growth rate (n=7 per group). This result is accompanied by a reduction in the tumor vascular density, as determined by CD34 or CD31 staining. The anti-FGF2 3F12E7 IgG tumor uptake was evaluated by nuclear medicine approaches, using this antibody radiolabeled with technetium-99m. In vivo SPECT/CT and ex vivo biodistribution studies reveled that 99mTc-anti-FGF2 IgG could efficiently achieved B16-F10 subcutaneous and metastatic tumors. Thus, these data suggest that the anti-FGF2 3F12E7 IgG may be a promising antitumor strategy for melanoma, as well as a potential imaging tool to be explored, working as a possible tracer to identify FGF2-positive tumors and map this angiogenic stimulus in the tumor microenvironment. Ethics committee (CAPPesq) approval number 0942/09
48
Baron, Olga [Verfasser]. « Role of basic fibroblast growth factor (FGF-2) during development of mesencephalic dopaminergic neurons of substantia nigra in mice / Olga Baron ». Hannover : Bibliothek der Tierärztlichen Hochschule Hannover, 2011. http://d-nb.info/1018928502/34.
Texte intégral
49
ZUNIGA, MEJIA BORJA AIMEE. « Identification et caracterisation d'une nouvelle isoforme du fibroblast growth factor-2 et de ses roles possibles au cours de l'embryogenese aviaire ». Paris 11, 1994. http://www.theses.fr/1994PA112340.
Texte intégralRésumé :
Le facteur de croissance peptidique fgf-2 (basic fgf) appartient a une famille de neuf membres caracterises par leur mitogenicite et leur grande affinite pour l'heparine ; ce sont les ligands de recepteurs-tyrosine kinases transmembranaires. Les fgf's jouent un role tres important au cours du developpement embryonnaire et dans l'etablissement du plan d'organisation des vertebres (induction du mesoderme, ebauche des membres etc. ). J'ai caracterise trois classes de transcripts du fgf-2 aviaire et analyse leur distribution chez l'embryon et chez l'adulte en utilisant les techniques de northern blot et de protections a la rnase. Notamment j'ai isole une nouvelle classe de transcripts, altfgf-2, produits par epissage alternatif du premier exon codant et pouvant en theorie coder pour une nouvelle proteine isoforme de fgf-2. Le messager altfgf-2 est exprime au cours de l'embryogenese aviaire mais non dans les tissus adultes ce qui suggerait que la proteine correspondante pourrait jouer un role particulier dans l'etablissement du plan d'organisation des vertebres. La production d'anticorps specifiques pour l'exon alt m'ont permis de montrer que le transcript altfgf-2 codait pour une proteine de 21. 5 kd dans l'embryon. L'etude par immunofluorescence de la localisation subcellulaire de la proteine a revele que, contrairement au fgf-2 classique, la proteine altfgf-2 etait toujours situee dans le cytoplasme, et plus particulierement dans le reticulum endoplasmique des cellules en culture. L'etude de la repartition spatiale et temporelle d'altfgf-2 dans l'embryon a montre que la proteine etait exprimee par les memes structures que le fgf-2 classique (tube neural, notocorde, myotomes, ebauches des membres et nephros) mais de facon plus restreinte. En particulier, dans le tube neural, la proteine est exprimee par les neurones moteurs lors de leur differenciation. L'expression de la proteine altfgf-2 restreinte a la region ventrale du tube neural s'inscrit dans le modele des inductions qui conduisent a l'etablissement de la polarite dorso-ventrale du tube neural. Ces resultats impliquent la proteine altfgf-2 dans le processus de differenciation des neurones moteurs et representent le premier exemple d'une proteine fgf plus specifiquement embryonaire et produite par epissage alternatif
50
Vercoutter-Edouart, Anne-Sophie. « Apport de l'analyse protéomique à l'étude de la signalisation du fibroblast growth factor-2 dans les cellules de cancer du sein ». Lille 1, 2000. https://pepite-depot.univ-lille.fr/LIBRE/Th_Num/2000/50376-2000-430.pdf.
Texte intégralRésumé :
Nous avons etudie la signalisation intracellulaire du fibroblast growth factor-2 dans les cellules de cancer du sein mcf-7 par analyse proteomique basee sur le couplage de l'electrophorese bidimensionnelle et de la spectrometrie de masse (maldi-tof et ms-ms). A l'aide d'inhibiteurs pharmacologiques et d'anticorps, nous avons montre que la stimulation des cellules mcf-7 par le fgf-2 declenche une augmentation de la tyrosine-phosphorylation du recepteur de haute affinite du fgf-2, du fgf receptor substrate-2 , de la kinase src, des p42/p44 mitogen-activated protein kinases (mapk), et d'une proteine de 30 kda. L'analyse en spectrometrie de masse maldi-tof nous a permis d'identifier cette proteine de 30 kda comme etant la cycline d2, element majeur de la regulation du cycle cellulaire. De plus, nos resultats suggerent que la phosphorylation de la cycline d2 est dependante de src mais pas des mapk. Nous avons ensuite etudie les modifications de synthese de proteines induites par le fgf-2 apres incorporation d'acides amines marques au 3 5s. Nous avons montre une augmentation de synthese de 4 proteines ( heat shock proteins hsp90 et hsp70, proliferating cell nuclear antigen (pcna) et transcriptionaly controlled tumor protein (tctp)) qui ont ete identifiees par spectrometrie de masse maldi-tof et ms-msDe plus, ces 4 proteines sont constitutivement surexprimees dans les cellules mcf-7 transfectees par l'oncogene ras. L'inhibition de la proliferation induite par le fgf-2 par la geldanamycine souligne l'importance de l'hsp90 dans la croissance des cellules de cancer du sein et son emergence comme cible therapeutique potentielle. Enfin, l'analyse proteomique des cellules cancereuses mammaires nous a permis de mettre en evidence pour la premiere fois que la quantite de la proteine 14-3-3 sigma est diminuee dans les cellules cancereuses par rapport aux cellules normales. La 14-3-3 sigma ayant ete tres recemment impliquee dans le controle de la progression du cycle cellulaire, ces donnees suggerent que cette proteine pourrait constituer un nouveau marqueur de cancerisation des cellules du sein. L'ensemble de ces travaux contribue a une meilleure comprehension du mecanisme d'action intracellulaire du fgf-2 dans les cellules de cancer du sein et montre les potentialites de l'analyse proteomique pour l'etude de la signalisation et plus generalement pour la recherche biomedicale